Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Liu Shi, Sarah Westwood, Alison L. Baird, Laura Winchester, Valerija Dobricic, Fabian Kilpert, Shengjun Hong, Andre Franke, Abdul Hye, Nicholas J. Ashton, Angharad R. Morgan, Isabelle Bos, Stephanie J. B. Vos, Noel J. Buckley, Mara ten Kate, Philip Scheltens, Rik Vandenberghe, Silvy Gabel, Karen Meersmans, Sebastiaan Engelborghs & 33 others Ellen E. de Roeck, Kristel Sleegers, Giovanni B. Frisoni, Olivier Blin, Jill C. Richardson, R. gis Bordet, José L. Molinuevo, Lorena Rami, Anders Wallin, Petronella Kettunen, Magda Tsolaki, Frans Verhey, Alberto Lleó, Daniel Alcolea, Julius Popp, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Peter Johannsen, Charlotte E. Teunissen, Yvonne Freund-Levi, Lutz Frölich, Cristina Legido-Quigley, Frederik Barkhof, Kaj Blennow, Henrik Zetterberg, Susan Baker, B. Paul Morgan, Johannes Streffer, Pieter Jelle Visser, Lars Bertram, Simon Lovestone, Alejo J. Nevado-Holgado

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
Original languageEnglish
JournalAlzheimer's and Dementia
DOIs
Publication statusPublished - 2019

Cite this

Shi, L., Westwood, S., Baird, A. L., Winchester, L., Dobricic, V., Kilpert, F., ... Nevado-Holgado, A. J. (2019). Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.06.4951
Shi, Liu ; Westwood, Sarah ; Baird, Alison L. ; Winchester, Laura ; Dobricic, Valerija ; Kilpert, Fabian ; Hong, Shengjun ; Franke, Andre ; Hye, Abdul ; Ashton, Nicholas J. ; Morgan, Angharad R. ; Bos, Isabelle ; Vos, Stephanie J. B. ; Buckley, Noel J. ; Kate, Mara ten ; Scheltens, Philip ; Vandenberghe, Rik ; Gabel, Silvy ; Meersmans, Karen ; Engelborghs, Sebastiaan ; de Roeck, Ellen E. ; Sleegers, Kristel ; Frisoni, Giovanni B. ; Blin, Olivier ; Richardson, Jill C. ; Bordet, R. gis ; Molinuevo, José L. ; Rami, Lorena ; Wallin, Anders ; Kettunen, Petronella ; Tsolaki, Magda ; Verhey, Frans ; Lleó, Alberto ; Alcolea, Daniel ; Popp, Julius ; Peyratout, Gwendoline ; Martinez-Lage, Pablo ; Tainta, Mikel ; Johannsen, Peter ; Teunissen, Charlotte E. ; Freund-Levi, Yvonne ; Frölich, Lutz ; Legido-Quigley, Cristina ; Barkhof, Frederik ; Blennow, Kaj ; Zetterberg, Henrik ; Baker, Susan ; Morgan, B. Paul ; Streffer, Johannes ; Visser, Pieter Jelle ; Bertram, Lars ; Lovestone, Simon ; Nevado-Holgado, Alejo J. / Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. In: Alzheimer's and Dementia. 2019.
@article{c62ac8f1b31d4ab8bf5f431ab8ad2d4f,
title = "Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay",
abstract = "Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.",
author = "Liu Shi and Sarah Westwood and Baird, {Alison L.} and Laura Winchester and Valerija Dobricic and Fabian Kilpert and Shengjun Hong and Andre Franke and Abdul Hye and Ashton, {Nicholas J.} and Morgan, {Angharad R.} and Isabelle Bos and Vos, {Stephanie J. B.} and Buckley, {Noel J.} and Kate, {Mara ten} and Philip Scheltens and Rik Vandenberghe and Silvy Gabel and Karen Meersmans and Sebastiaan Engelborghs and {de Roeck}, {Ellen E.} and Kristel Sleegers and Frisoni, {Giovanni B.} and Olivier Blin and Richardson, {Jill C.} and Bordet, {R. gis} and Molinuevo, {Jos{\'e} L.} and Lorena Rami and Anders Wallin and Petronella Kettunen and Magda Tsolaki and Frans Verhey and Alberto Lle{\'o} and Daniel Alcolea and Julius Popp and Gwendoline Peyratout and Pablo Martinez-Lage and Mikel Tainta and Peter Johannsen and Teunissen, {Charlotte E.} and Yvonne Freund-Levi and Lutz Fr{\"o}lich and Cristina Legido-Quigley and Frederik Barkhof and Kaj Blennow and Henrik Zetterberg and Susan Baker and Morgan, {B. Paul} and Johannes Streffer and Visser, {Pieter Jelle} and Lars Bertram and Simon Lovestone and Nevado-Holgado, {Alejo J.}",
year = "2019",
doi = "10.1016/j.jalz.2019.06.4951",
language = "English",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",

}

Shi, L, Westwood, S, Baird, AL, Winchester, L, Dobricic, V, Kilpert, F, Hong, S, Franke, A, Hye, A, Ashton, NJ, Morgan, AR, Bos, I, Vos, SJB, Buckley, NJ, Kate, MT, Scheltens, P, Vandenberghe, R, Gabel, S, Meersmans, K, Engelborghs, S, de Roeck, EE, Sleegers, K, Frisoni, GB, Blin, O, Richardson, JC, Bordet, RG, Molinuevo, JL, Rami, L, Wallin, A, Kettunen, P, Tsolaki, M, Verhey, F, Lleó, A, Alcolea, D, Popp, J, Peyratout, G, Martinez-Lage, P, Tainta, M, Johannsen, P, Teunissen, CE, Freund-Levi, Y, Frölich, L, Legido-Quigley, C, Barkhof, F, Blennow, K, Zetterberg, H, Baker, S, Morgan, BP, Streffer, J, Visser, PJ, Bertram, L, Lovestone, S & Nevado-Holgado, AJ 2019, 'Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay' Alzheimer's and Dementia. https://doi.org/10.1016/j.jalz.2019.06.4951

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. / Shi, Liu; Westwood, Sarah; Baird, Alison L.; Winchester, Laura; Dobricic, Valerija; Kilpert, Fabian; Hong, Shengjun; Franke, Andre; Hye, Abdul; Ashton, Nicholas J.; Morgan, Angharad R.; Bos, Isabelle; Vos, Stephanie J. B.; Buckley, Noel J.; Kate, Mara ten; Scheltens, Philip; Vandenberghe, Rik; Gabel, Silvy; Meersmans, Karen; Engelborghs, Sebastiaan; de Roeck, Ellen E.; Sleegers, Kristel; Frisoni, Giovanni B.; Blin, Olivier; Richardson, Jill C.; Bordet, R. gis; Molinuevo, José L.; Rami, Lorena; Wallin, Anders; Kettunen, Petronella; Tsolaki, Magda; Verhey, Frans; Lleó, Alberto; Alcolea, Daniel; Popp, Julius; Peyratout, Gwendoline; Martinez-Lage, Pablo; Tainta, Mikel; Johannsen, Peter; Teunissen, Charlotte E.; Freund-Levi, Yvonne; Frölich, Lutz; Legido-Quigley, Cristina; Barkhof, Frederik; Blennow, Kaj; Zetterberg, Henrik; Baker, Susan; Morgan, B. Paul; Streffer, Johannes; Visser, Pieter Jelle; Bertram, Lars; Lovestone, Simon; Nevado-Holgado, Alejo J.

In: Alzheimer's and Dementia, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

AU - Shi, Liu

AU - Westwood, Sarah

AU - Baird, Alison L.

AU - Winchester, Laura

AU - Dobricic, Valerija

AU - Kilpert, Fabian

AU - Hong, Shengjun

AU - Franke, Andre

AU - Hye, Abdul

AU - Ashton, Nicholas J.

AU - Morgan, Angharad R.

AU - Bos, Isabelle

AU - Vos, Stephanie J. B.

AU - Buckley, Noel J.

AU - Kate, Mara ten

AU - Scheltens, Philip

AU - Vandenberghe, Rik

AU - Gabel, Silvy

AU - Meersmans, Karen

AU - Engelborghs, Sebastiaan

AU - de Roeck, Ellen E.

AU - Sleegers, Kristel

AU - Frisoni, Giovanni B.

AU - Blin, Olivier

AU - Richardson, Jill C.

AU - Bordet, R. gis

AU - Molinuevo, José L.

AU - Rami, Lorena

AU - Wallin, Anders

AU - Kettunen, Petronella

AU - Tsolaki, Magda

AU - Verhey, Frans

AU - Lleó, Alberto

AU - Alcolea, Daniel

AU - Popp, Julius

AU - Peyratout, Gwendoline

AU - Martinez-Lage, Pablo

AU - Tainta, Mikel

AU - Johannsen, Peter

AU - Teunissen, Charlotte E.

AU - Freund-Levi, Yvonne

AU - Frölich, Lutz

AU - Legido-Quigley, Cristina

AU - Barkhof, Frederik

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Baker, Susan

AU - Morgan, B. Paul

AU - Streffer, Johannes

AU - Visser, Pieter Jelle

AU - Bertram, Lars

AU - Lovestone, Simon

AU - Nevado-Holgado, Alejo J.

PY - 2019

Y1 - 2019

N2 - Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

AB - Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071719989&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31495601

U2 - 10.1016/j.jalz.2019.06.4951

DO - 10.1016/j.jalz.2019.06.4951

M3 - Article

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

ER -